Tresiba® is a once-daily long-acting insulin. Tresiba® is similar to the insulin made by your body and helps your body to reduce your blood sugar level.
Tresiba® offers the flexibility of once-daily dosing at any time of the day.
Life can be unpredictable—if you forget or mistime a dose, take your Tresiba® as soon as you remember, keeping in mind there should be at least 8 hours between your doses.
Tresiba® comes in the preferred and easy-to-use FlexTouch® pen
100 Units/mL, which delivers a maximum of 80 Units per injection, counting up by 1 Unit
200 Units/mL, which delivers a maximum of 160 Units per injection, counting up by 2 Units
Tresiba® is also available in a Penfill® 3 mL cartridge that contains 100 Units/mL, for use in the NovoPen® 4 and NovoPen® 5.
Watch the FlexTouch® video to learn more
Get to know Tresiba®
Tresiba® dosing considerations
Together with your healthcare team, you will decide:
How much Tresiba® you will need each day and when to take it.
When to measure your blood sugar levels and how to adjust your dose based on the results.
Make Tresiba® part of your daily routine: For example, your healthcare team may recommend testing your blood sugar level and dosing your Tresiba® as part of your morning routine
As with any insulin, there is a chance that your blood sugar may get too low (<4 mmol/L) when you take Tresiba®. This is called hypoglycemia, and it happens when you either have too much insulin or not enough sugar in your body. It may also happen if you drink alcohol, exercise more than usual, eat too little or miss a meal.
To help reduce the risk of getting low blood sugar, it is important to take your insulin as instructed by your diabetes healthcare team and let them know if you want to change your diet or exercise routine.
If you are a patient or a healthcare professional, you can access more information about Tresiba®
by clicking the relevant button below
Covered by most provincial formularies across Canada†
Ask your healthcare team today if Tresiba® is right for you!
* Clinical significance has not been established.
† Public formulary coverage is available in all provinces with the exception of British Columbia.
‡ Tresiba® was previously covered as part of the “Exceptional Medications” section of the RAMQ List of Medications.
RAMQ, official mark of the Régie de l'assurance maladie du Québec.
Simplified Chinese (CN)
Traditional Chinese (HK)
Tresiba® is indicated for once-daily treatment of adults with diabetes mellitus to improve glycemic control. Tresiba® is also indicated for the treatment of pediatric patients (≥2 years old) with type 1 diabetes mellitus.
Not recommended for treatment of diabetic ketoacidosis.
During episodes of hypoglycemia
Most serious warnings and precautions:
Hypoglycemia is the most common adverse effect of insulin.
Glucose monitoring is required
Uncorrected hypo- or hyperglycemic reactions can cause loss of consciousness, coma and even death
Use caution and medical supervision when converting insulin products
Inspect visually prior to administration and only use if solution appears clear and colourless
Do not mix with any other insulin, administer intravenously or use in insulin infusion pumps
Other relevant warnings and precautions:
Refer to respective product monographs for concomitant oral antidiabetic agents for their warnings and precautions
Stress or concomitant illness, especially infections and febrile conditions, may change insulin requirements
Tresiba® should not be diluted
Combination with thiazolidinediones (TZD) not indicated in type 2 diabetes; can cause heart failure and edema
Risks associated with sharing insulin delivery devices
Risk of hypokalemia
Dosing may need to be adjusted in patients with renal and/or hepatic impairment
Risk of immune responses (e.g., systemic allergic reactions, antibody production, or lipodystrophy and cutaneous amyloidosis)
Treatment with Tresiba® can be considered during pregnancy, if the benefit justifies possible risks and if clinically needed
For more information:
Please consult the Product Monograph at here for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.
The Product Monograph is also available by calling us at 1-800-465-4334.